Review – Testis CancerEuropean Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I☆
Section snippets
Diagnosis and staging
In 2004 the first consensus paper on diagnostics and treatment in testicular cancer was prepared by the European Germ Cell Cancer Consensus Group (EGCCCG) [1]. In this interdisciplinary process by medical oncologists, urologic surgeons, radiation oncologists and pathologists the methodology of evidence-based medicine (EBM) was applied (Table 1) [2], [3]. This paper is an update with the new data emerged since 2002 integrated and prepared again on the basis of evidence-based medicine.
Orchiectomy
As a rule orchiectomy is performed before any further treatment (Table 3). Orchiectomy should be scheduled timely (within 1 wk). However, there is no need for emergency (within 24 h) surgery. The results of the tumour marker determination should be available before surgery and have to be reevaluated thereafter to determine the half-life kinetic (half-life time: AFP < 7 d; ß-HCG < 3 d).
Radical orchiectomy is performed through an inguinal incision [26], [27], [28]. Any scrotal violation for biopsy or
Testicular biopsy in patients with gonadal germ cell cancer
Intratubular germ cell neoplasia (TIN/CIS) is defined as a malignant preinvasive testicular germ cell lesion. In patients with TIN, the cumulative probability for the development of a testicular tumour is 70% after 7 yr [EBM IIB: 36]. Up to 9% of patients with testicular tumours harbour TIN within the contralateral “normal” testicle, which is detectable by open biopsy, best performed as a double biopsy to increase the detection rate to >99% [37], [38] (Table 4). For patients with testicular
Histological examination of germ cell cancer
It is recommended to completely laminate the testicular specimen in transverse sections. Additional sections have to be taken from the spermatic cord. For full histological examination of the tumour, it is necessary to obtain one block per centimetre of tumour, not less than a total of three blocks, as well as blocks from the peritumoural region and of remote testicular tissue. Further samples have to be taken from the funicular resection margin and from the spermatic cord within a 1-cm
Treatment-associated fertility issues and sperm banking
In patients of reproductive age, baseline fertility assessment should be performed, including the determination of total testosterone level, luteinising hormone, follicle-stimulating hormone, and semen analysis. The patient must be informed about and offered the possibility of cryoconservation, preferably carried out before orchiectomy [47], [50], [104], [105], [106], [107], [108]. Patients with bilateral testicular tumours, or a testicular tumour with contralateral TIN and with severe oligo-,
Treatment of patients with seminoma CS I
Despite normal CT scans, up to 32% of patients with CS I seminoma can relapse if no adjuvant treatment is given [57], [115], [116]. Nevertheless, the cure rate in CS I seminoma patients is almost 100% and can be achieved with three strategies: surveillance with salvage irradiation or chemotherapy at relapse, adjuvant chemotherapy with single-agent carboplatin, and—with the most mature follow-up data—adjuvant radiation treatment [117], [118], [119], [120]. Tumour size >4 cm and rete testis
Treatment of patients with non-seminoma CS I
If treatment is performed correctly, the cure rate of patients with non-seminoma CS I should be 99%, regardless of the management chosen [67], [140]. In the case of surveillance, the relapse rate is 27–30% when considering a long-term follow up of ≤20 yr [71], [140]. Relapses occur in the retroperitoneum in 54–78% of patients, and in the lung in 13–31%, but are very rarely found in more than one visceral organ [140], [141], [142].
VI of the primary tumour is the most important prognostic
Conflicts of interest
The authors have nothing to disclose.
Acknowledgements
This consensus document was made possible by the input of the participants of the 2006 consensus conference who discussed and prepared this update of the 2002 consensus meeting.
All participants particularly like to thank Dr M. Pilar Laguna, Mrs Sonja van Rees Vellinga, and Karin Plass for organizing the meeting.
References (164)
- et al.
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)
Ann Oncol
(2004) - et al.
Extragonadal retroperitoneal germ cell tumor: evidence of origin in the testis
Ann Oncol
(2002) - et al.
Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors
Ann Oncol
(2002) - et al.
Occurrence of testicular cancer in patients operated on for cryptorchidism and inguinal hernia
J Urol
(1991) - et al.
Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis
J Urol
(2005) - et al.
a-Foetoprotein heterogeneity: what is its value in managing patients with germ cell tumours?
Clin Oncol (R Coll Radiol)
(1996) Testicular cancer
Curr Probl Cancer
(1998)- et al.
Delayed orchiectomy after chemotherapy for metastatic nonseminomatous germ cell tumors
J Urol
(1996) - et al.
A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary?
J Urol
(1995) - et al.
The clinical implications of procedural deviations during orchiectomy for nonseminomatous testis cancer
J Urol
(1995)
Accuracy of frozen section examination of testicular tumors of uncertain origin
Eur Urol
Value of frozen section examination for the management of nonpalpable incidental testicular tumors
Eur Urol
Frozen section analysis-guided organ-sparing approach in testicular tumors: technique, feasibility, and long-term results
Urology
Organ preserving surgery of malignant germ cell tumors
J Urol
Organ sparing surgery for malignant germ cell tumor of the testis
J Urol
Carcinoma in situ testis, the progenitor of testicular germ cell tumors: a clinical review
Ann Oncol
Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy
Eur Urol
Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group
J Urol
Management of extragonadal germ cell tumors and the significance of bilateral testicular biopsies
Ann Oncol
Testicular carcinoma in situ in patients with extragonadal germ-cell tumours: the clinical role of pre-treatment biopsy
Ann Oncol
Effect of chemotherapy on carcinoma in situ of the testis
Ann Oncol
Handling and reporting of biopsy and surgical specimens of testicular cancer
Eur Urol
Prognostic factors for relapse in stage I testicular seminoma treated with surveillance
J Urol
Risk-adapted treatment of clinical stage I non-seminoma testis cancer
Eur J Cancer
Long term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors
J Urol
Risk-related adjuvant chemotherapy for stage I non-seminoma of the testis
Clin Oncol
Tumor proliferative activity is predictive of pathological stage in clinical stage A non-seminomatous testicular germ cell tumors
J Urol
Clinical stage I testis cancer: long term outcome of patients on surveillance
J Urol
The role of computed tomographic examination of the pelvis in the management of testicular germ cell tumours
Clin Radiol
Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors
J Urol
Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse
Eur J Cancer
A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: a 10-year follow up
J Urol
A rational approach to managing stage I nonseminomatous germ cell cancer
Urol Clin North Am
Imaging of the thorax in the management of germ cell testicular tumours
Clin Radiol
Imaging of intrathoracic metastases of nonseminomatous germ cell tumors
Chest Surg Clin N Am
Chest staging in testis cancer patients: imaging modality selection based upon risk assessment as determined by abdominal computerized tomography scan results
J Urol
Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell tumor using size criteria of retroperitoneal lymph nodes
J Urol
Positron emissions tomography in urological oncology
J Urol
Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study of 50 patients
Urology
Positron emission tomography in the clinical staging of patients with stage I and II germ cell tumors
Urology
Practice guidelines, a new reality in medicine II. Methods of developing guidelines
Arch Intern Med
Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome
Cancer
Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors
J Natl Cancer Inst
The incidence, prognosis, clinical and histological characteristics, treatment and outcome of patients with bilateral germ cell testicular cancer in Hungary
J Cancer Res Clin Oncol
Management and outcome of bilateral testicular germ cell tumors: twenty-five year experience in Munich
Acta Oncol
Clinical epidemiology of testicular germ cell tumors
World J Urol
Epidemiology of testicular cancer: an overview
Int J Cancer
Risk of testicular cancer in men with abnormal semen characteristics: cohort study
BMJ
Histological evidence of testicular dysgenesis in contralateral biopsies from 218 patients with testicular germ cell cancer
J Pathol
Cited by (0)
- ☆
Please visit www.eu-acme.org/europeanurology to read and answer questions on-line. The EU-ACME credits will then be attributed automatically.